ArticleESMO real world data and digital oncology2024

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC.

Y Uehara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.